MarketPulse

RYTELO

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Geron Sets May 6 Earnings Call as RYTELO Expansion Accelerates

Geron Corporation will report Q1 2026 results on May 6, advancing its approved telomerase inhibitor RYTELO and Phase 3 myelofibrosis trial.
GERNfinancial resultsclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Geron Corporation

Geron Strengthens Legal Leadership With Williams Appointment as Chief Legal Officer

Geron appoints Timothy Williams as Chief Legal Officer and EVP, strengthening management amid commercial expansion in blood cancer treatments.
GERNbiopharmaceuticalexecutive appointment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Geron to Share Pipeline Progress at Needham Conference as RYTELO® Gains Market Traction

Geron Corporation will discuss its commercial-stage telomerase inhibitor platform at the Needham Healthcare Conference on April 13, highlighting RYTELO® adoption and ongoing Phase 3 trials in myelofibrosis.
GERNclinical trialbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Geron Posts $184M in Annual RYTELO Revenue, Guides 2026 Sales Growth

Geron's RYTELO generated $184M in 2025 revenue. The company guides 2026 sales of $220-240M, driven by domestic expansion and international opportunities.
GERNfinancial resultsFDA approval